Cevidoplenib (dimesylate)
Cevidoplenib is an orally available inhibitor of spleen tyrosine kinase (Syk), with potential anti-inflammatory and immunomodulating activities[1][2].
Product Specifications
CAS Number
[2043659-93-2]
Product Name Alternative
SKI-O-703 (dimesylate)
UNSPSC
12352005
Target
Syk
Type
Reference compound
Related Pathways
Protein Tyrosine Kinase/RTK
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/cevidoplenib-dimesylate.html
Concentration
10mM
Purity
98.96
Solubility
DMSO : 25 mg/mL (ultrasonic)
Smiles
O=C(C1CC1)C2=CN(C)C3=C2C=C(NC4=NC=CC(N5N=C(C)C(CN6OC[C@@H](O)C6)=C5)=N4)C=C3.CS(=O)(O)=O.CS(=O)(O)=O
Molecular Formula
C27H35N7O9S2
Molecular Weight
665.74
References & Citations
[1]International Nonproprietary Names for Pharmaceutical Substances (INN) . WHO Drug Information, Vol. 31, No. 4, 2017.|[2]cevidoplenib dimesylate.
Shipping Conditions
Room Temperature
Storage Conditions
4°C (Powder, sealed storage, away from moisture)
Scientific Category
Reference compound1
Clinical Information
Phase 2
Available Sizes
Explore Other Products
Browse additional items from our catalog
MAPK10 (Mitogen-activated Protein Kinase 10, MAPK 10, MAP Kinase 10, PRKM10, c-Jun N-terminal Kinase 3, JNK3, JNK3A, MAP Kinase p49 3F12, p493F12, p54bSAPK, Stress-activated Protein Kinase 1b, SAPK1b, Stress-activated Protein Kinase JNK3, FLJ12099, FLJ33785, MGC50974) (FITC)
MPHOSPH6 (M-phase Phosphoprotein 6, MPP, MPP-6, MPP6) (MaxLight 650)
